Result for
Tag: treatment
May 25, 2021
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19
The IL-6 inhibitor tocilizumab was not associated with a reduction in 90-day mortality (HR=0.64, 95%CI 0.25-1.65) in a follow-up of a randomized, placebo-controlled trial of patients hospitalized with COVID-19 who were receiving oxygen but did not require high-flow or mechanical ventilation (n=130). However, in a subgroup analysis including participants with baseline C-reactive protein levels greater…
May 20, 2021
Tocilizumab in the Treatment of COVID-19 – a Meta-Analysis
The immunosuppressive monoclonal antibody treatment tocilizumab (TCZ) was associated with a 11% reduction in risk for all-cause 28- and 30-day mortality compared to placebo/control in a systematic review and meta-analysis of 8 randomized trials, which included 6,481 patients mostly with severe but non-critical COVID-19. TCZ was also associated with reduced risk of mechanical ventilation, ICU…
May 19, 2021
Colchicine in Patients Admitted to Hospital with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial
[Pre-print, not peer-reviewed] The anti-inflammatory drug colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progression to invasive mechanical ventilation (IVM) or death among adults hospitalized with COVID-19 in an analysis of the RECOVERY trial (a randomized, placebo-controlled open-label trial). In both the treatment (n=5610) and control (n=5730)…
May 17, 2021
Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised Controlled, Open-Label, Platform Trial
Among patients hospitalized with COVID-19, convalescent plasma treatment did not improve 28-day mortality (RR = 1.0), time to hospital discharge (RR = 0.99), or result in a significant difference in the proportion of patients who either received invasive mechanical ventilation or died (RR = 0.99), according to results from the RECOVERY trial in the UK….
May 14, 2021
Interferon-a-2b Aerosol Inhalation Is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019
A retrospective analysis of patients with COVID-19 (N=1,401) found that patients treated with IFN-α-2b aerosol inhalation in combination with standard treatment had a 61% lower risk of ICU admission, mechanical ventilation, and death, even after adjusting for comorbidities, baseline disease severity, and antiviral use. A subgroup analysis found that delayed IFN treatment was associated with…
Ivermectin in Combination with Doxycycline for Treating COVID-19 Symptoms: A Randomized Trial
A randomized, blinded, placebo-controlled trial of ivermectin combined with doxycycline for patients with mild-to-moderate COVID-19 symptoms (N=400) found that treated patients had a shorter median time to recovery (7 vs. 9 days) and were more likely to be SARS-CoV-2 negative by RT-PCR at two weeks follow-up. However, the investigators note that the majority of study…
May 12, 2021
Remdesivir for Coronavirus Disease 2019 (COVID-19): A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
A systematic review and meta-analysis of 5 randomized placebo-controlled trials (n=7,540 total participants) found no significant evidence that remdesivir (100 mg over 10 days) reduced all-cause mortality (RR=0.94, CI 0.82-1.07), clinical progression (RR=1.08, CI 0.99-1.18), or diarrhea (RR=0.82, CI 0.40-1.66). The authors conducted a trial sequential analysis and found that the meta-analysis was underpowered to…
A Randomized Double-Blind Controlled Trial of Convalescent Plasma in Adults with Severe COVID-19
Participants with severe COVID-19 randomized to receive convalescent plasma (n=150) had significantly lower 28-day mortality (OR=0.44, 95% CI: 0.22-.91) compared to those receiving controlled plasma (n=73) in a randomized double-blind controlled trial conducted in New York and Brazil. However, no significant improvement in clinical status, as measured on an ordinal scale, was observed at 28…
Inappropriate Antibiotic Use in the COVID-19 Era: Factors Associated with Inappropriate Prescribing and Secondary Complications
34% of COVID-19 patients in a multicenter cohort in Spain (n=13,932) were inappropriately prescribed antibiotics, defined as the patient not fulfilling any accepted criteria for use of antibiotics such as shock, sepsis, or coinfections. Patients admitted to the hospital early in the pandemic (February to March 2020) and presenting with dry cough, fever, and flu-like…
May 10, 2021
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-Analysis
A systematic review and meta-analysis found that patients with COVID-19 who received convalescent plasma in randomized clinical trials (n=10 studies) and matched control studies (n=20 studies) had lower mortality rates compared with patients receiving standard treatments (OR = 0.58). In addition, exploratory analysis found that early treatment (within 3 days of hospital admission) of higher…
Previous page Next page